<DOC>
	<DOCNO>NCT00050661</DOCNO>
	<brief_summary>This study design study disease relapse NBUVB administration Daclizumab/placebo alters disease relapse .</brief_summary>
	<brief_title>To Study Use Humanized CD25 Preventing Relapse Psoriasis Vulgaris</brief_title>
	<detailed_description>The first part study involve NB-UVB light treatment , well-established treatment treat psoriasis . In second part , test drug know Humanized CD25 Monoclonal Antibody ( anti-TAC ) placebo prevent disease relapse . Anti-TAC injectable medicine also design treat psoriasis block part immune system believe contribute disease .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Daclizumab</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<criteria>Inclusion Criteria 1 . Male female patient chronic psoriasis vulgaris ( disease stable worsen &gt; 6 month ) . Patients age 16 21 consider case case basis . For patient age 18 , parental consent obtain . 2 . Extensive skin involvement . 3 . Scale , thickness , erythema individual psoriasis lesion least moderate intensity . 4 . Psoriasis treat emollient 2 week prior treatment 5 . Patients active psoriatic arthritis , accompany psoriasis vulgaris involve 5 % body surface . 6 . Patients appropriate treatment UVB . 1 . Positive serology HIV , Hepatitis B , Hepatitis C. 2 . Positive βHCG titer . For woman childbearing potential , unwillingness inability use contraceptive device study negative βHCG . 3 . Guttate psoriasis , pustular psoriasis , whole body erythroderma . 4 . Active infection persistent fever unknown origin . 5 . Major concurrent illness , could worsen follow treatment antiTAC .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>psoriasis</keyword>
	<keyword>Cyclosporine</keyword>
	<keyword>Daclizamub</keyword>
	<keyword>anti-TAC</keyword>
	<keyword>dermatology</keyword>
	<keyword>skin</keyword>
	<keyword>lesion</keyword>
</DOC>